TTrialPathMatch Me to Trials
← Back to trials
RecruitingMetabolic Dysfunction-associated Steatotic Liver Disease

Advanced Fibrosis Detection for MASLD in Primary Care

Eligible age

18+ yrs

Accepts

All genders

Locations

1 state

Healthy volunteers

No

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This proposal evaluates the implementation of a novel, non-interruptive, electronic health record alert for metabolic dysfunction-associated steatotic liver disease (MASLD) fibrosis risk assessment in primary care patients with MASLD using a stepped wedge, cluster randomized design. This work will generate generalizable data to dramatically enhance MASLD management in primary care.

Sponsor: Medical University of South Carolina

You may qualify if…

  • Patients with a diagnosis code for MASLD
  • Type 2 diabetes mellitus will
  • 1\. All physicians, physician assistants, and nurse practitioners delivering primary care during the intervention phase of the study.

You may not qualify if…

  • All patients with cirrhosis, complications of cirrhosis (e.g. portal hypertension, hepatic encephalopathy), hepatocellular carcinoma, or previous liver transplant will be excluded.
  • pregnant women.
  • Clinicians Clinicians will also be study participants, as we will be surveying them for feedback on the MASLD fibrosis risk assessment intervention. The MUSC primary care network at last count employed 122 clinicians across the 27 primary care practices.
  • None

Where it's recruiting

South Carolina

Charleston

Source: ClinicalTrials.gov · NCT07159386 · last updated 2026-03-31

Advanced Fibrosis Detection for MASLD in Primary Care · TrialPath